suramin has been researched along with Carcinoma, Transitional Cell in 7 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined the ability of suramin to inhibit thymidine uptake and decrease cellular proliferation in 4 transitional cell carcinoma cell lines grown in vitro to determine if suramin might be a new candidate drug of treatment for patients with superficial bladder cancer." | 3.69 | Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. ( Cooper, M; Linehan, WM; Trahan, EE; Venzon, D; Walther, MM, 1994) |
| "Suramin is a polysulfonated naphthylurea that inhibits proliferation and DNA synthesis of transitional cell carcinoma cell lines." | 2.71 | A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder. ( Figg, WD; Linehan, WM; Uchio, EM; Walther, MM, 2003) |
| "Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects." | 2.71 | Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. ( Banks, RE; Cranston, D; Crew, J; Harris, AL; Joel, SP; Jones, A; Le Monnier, K; Ord, JJ; Roberts, IS; Rogers, MA; Streeter, E, 2005) |
| "Suramin has been shown to block the binding of epidermal growth factor (EGF) to its receptors, which are found in large amounts in bladder cancers." | 2.39 | Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. ( Figg, WD; Linehan, WM; Walther, MM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uchio, EM | 1 |
| Linehan, WM | 3 |
| Figg, WD | 2 |
| Walther, MM | 3 |
| Ord, JJ | 1 |
| Streeter, E | 1 |
| Jones, A | 2 |
| Le Monnier, K | 1 |
| Cranston, D | 2 |
| Crew, J | 1 |
| Joel, SP | 1 |
| Rogers, MA | 1 |
| Banks, RE | 1 |
| Roberts, IS | 1 |
| Harris, AL | 2 |
| Graham, SD | 1 |
| Napalkov, P | 1 |
| Oladele, A | 1 |
| Keane, TE | 1 |
| Petros, JA | 1 |
| Clarke, HS | 1 |
| Kassabian, VS | 1 |
| Dillehay, DL | 1 |
| Droller, MJ | 1 |
| Trahan, EE | 1 |
| Cooper, M | 1 |
| Venzon, D | 1 |
| Fujiyama, C | 1 |
| Fuggle, S | 1 |
| Bicknell, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer[NCT00006476] | Phase 1 | 15 participants (Anticipated) | Interventional | 2000-10-31 | Completed | ||
| A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder[NCT00001381] | Phase 1 | 18 participants | Interventional | 1994-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for suramin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; | 1996 |
2 trials available for suramin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Hum | 2003 |
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitiona | 2005 |
4 other studies available for suramin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Intravesical suramin in the prevention of transitional cell carcinoma.
Topics: Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Female; Methylnitrosourea; Rats | 1995 |
This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Screening Assays, Antitumor; Humans; Neopl | 1994 |
Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines.
Topics: Animals; Carcinoma, Transitional Cell; Cell Division; Cell Line; DNA, Neoplasm; Drug Screening Assay | 1994 |
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Topics: Acetylcysteine; Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma, Transitiona | 2001 |